Tumor-targeted bispecific antibodies effectively inhibit oncogenic pathways while minimizing toxicity

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Hyperactivated Wnt signaling drives cancers like colorectal and pancreatic cancer.
• Direct Wnt inhibition causes severe toxicities due to its role in normal tissues.
• Targeting oncogenic pathways requires specificity to avoid off-target effects.

Purpose of the Study:

• To design bispecific antibodies for targeted inhibition of oncogenic signaling pathways in cancer cells.
• To develop tumor-targeted therapies that minimize toxicity in normal tissues.
• To establish a framework for creating cell type-specific therapeutics.

Main Methods:

• Utilized single-cell technologies to identify tumor-specific receptors.
• Designed bispecific antibodies targeting tumor-associated calcium signal transducer 2 (TROP2) and Wnt signaling.
• Developed bispecific antibodies targeting fibroblast growth factor receptor 1 (FGFR1) and epidermal growth factor receptor (EGFR).

Main Results:

• A TROP2-targeted anti-Frizzled bispecific antibody inhibited Wnt signaling in preclinical models.
• This targeted inhibition showed minimal effects on normal intestinal tissue.
• The study demonstrated the feasibility of developing tumor-targeted, toxicity-sparing bispecific antibodies.

Conclusions:

• Bispecific antibodies can selectively inhibit oncogenic pathways in cancer cells.
• This strategy enhances therapeutic efficacy and tolerability by sparing normal tissues.
• The developed framework offers a promising approach for designing targeted cancer therapies with reduced toxicity.